VRTX
Vertex Pharmaceuticals Incorporated NASDAQ Listed Jul 24, 1991$424.84
Mkt Cap $107.8B
52w Low $362.50
42.9% of range
52w High $507.92
50d MA $450.25
200d MA $435.70
P/E (TTM)
27.4x
EV/EBITDA
23.1x
P/B
5.8x
Debt/Equity
0.2x
ROE
21.2%
P/FCF
36.3x
RSI (14)
—
ATR (14)
—
Beta
0.37
50d MA
$450.25
200d MA
$435.70
Avg Volume
1.4M
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
50 Northern Avenue · Boston, MA 02210 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | AMC | 4.23 | 4.06 | -4.0% | 429.85 | +0.5% | -1.3% | -0.5% | -1.1% | — | — | — |
| Feb 12, 2026 | AMC | 5.11 | 5.03 | -1.6% | 465.02 | +1.4% | +5.7% | +2.6% | +1.1% | +0.9% | +2.6% | — |
| Nov 3, 2025 | AMC | 4.57 | 4.80 | +5.0% | 426.00 | -1.7% | -1.0% | -2.1% | -2.3% | -3.9% | -1.1% | — |
| Aug 4, 2025 | AMC | 4.29 | 4.52 | +5.4% | 472.27 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% | — |
| May 5, 2025 | AMC | 4.25 | 4.06 | -4.5% | 500.19 | -6.9% | -10.0% | -13.1% | -14.1% | -15.0% | -12.2% | — |
| Feb 10, 2025 | AMC | 4.02 | 3.98 | -1.0% | 469.97 | -2.2% | -3.1% | -3.6% | -1.6% | -2.3% | -1.7% | — |
| Nov 4, 2024 | AMC | 4.14 | 4.38 | +5.8% | 472.80 | +2.2% | +5.7% | +4.4% | +6.3% | +9.3% | +6.1% | — |
| Aug 1, 2024 | AMC | -11.63 | -12.83 | -10.3% | 505.78 | -2.8% | -2.2% | -5.7% | -6.2% | -7.9% | -7.9% | — |
| May 6, 2024 | AMC | 4.06 | 4.76 | +17.2% | 402.50 | +1.0% | +1.9% | +4.1% | +4.1% | +5.0% | +6.8% | — |
| Feb 5, 2024 | AMC | 4.10 | 4.20 | +2.4% | 428.89 | -0.0% | -3.0% | -2.3% | -1.4% | -1.4% | -2.4% | — |
| Nov 6, 2023 | AMC | 3.97 | 4.08 | +2.8% | 385.76 | -2.2% | -1.9% | -2.3% | -4.5% | -3.1% | -1.8% | — |
| Aug 1, 2023 | AMC | 3.88 | 3.89 | +0.3% | 347.74 | +0.6% | +3.1% | +0.0% | -2.1% | -0.7% | -0.9% | — |
| May 1, 2023 | AMC | 3.00 | 3.05 | +1.7% | 345.00 | +0.0% | +0.3% | +0.4% | +0.5% | +0.9% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Canaccord Genuity | Maintains | Hold → Hold | — | $423.24 | $423.66 | +0.1% | +1.0% | +0.2% | +1.6% | +0.3% | +1.0% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $446.78 | $446.08 | -0.2% | -2.4% | -1.5% | -0.6% | -1.1% | -2.5% |
| Mar 18 | Maxim Group | Upgrade | Hold → Buy | — | $462.49 | $462.80 | +0.1% | -2.4% | -1.0% | -1.8% | -2.4% | -3.0% |
| Mar 11 | Truist | Maintains | Buy → Buy | — | $499.17 | $497.88 | -0.3% | -1.4% | -4.2% | -6.0% | -6.6% | -7.3% |
| Mar 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $460.87 | $482.25 | +4.6% | +8.3% | +6.8% | +3.7% | +1.8% | +1.1% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $460.87 | $482.25 | +4.6% | +8.3% | +6.8% | +3.7% | +1.8% | +1.1% |
| Mar 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $460.87 | $482.25 | +4.6% | +8.3% | +6.8% | +3.7% | +1.8% | +1.1% |
| Mar 10 | Citigroup | Maintains | Buy → Buy | — | $460.87 | $482.25 | +4.6% | +8.3% | +6.8% | +3.7% | +1.8% | +1.1% |
| Mar 10 | BofA Securities | Maintains | Buy → Buy | — | $460.87 | $482.25 | +4.6% | +8.3% | +6.8% | +3.7% | +1.8% | +1.1% |
| Feb 17 | Barclays | Maintains | Overweight → Overweight | — | $491.47 | $489.46 | -0.4% | -2.9% | -4.3% | -4.5% | -3.0% | -2.1% |
| Feb 17 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $491.47 | $489.46 | -0.4% | -2.9% | -4.3% | -4.5% | -3.0% | -2.1% |
| Feb 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $491.47 | $489.46 | -0.4% | -2.9% | -4.3% | -4.5% | -3.0% | -2.1% |
| Feb 17 | Canaccord Genuity | Maintains | Hold → Hold | — | $491.47 | $489.46 | -0.4% | -2.9% | -4.3% | -4.5% | -3.0% | -2.1% |
| Feb 13 | RBC Capital | Maintains | Outperform → Outperform | — | $465.02 | $471.65 | +1.4% | +5.7% | +2.6% | +1.1% | +0.9% | +2.6% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $465.02 | $471.65 | +1.4% | +5.7% | +2.6% | +1.1% | +0.9% | +2.6% |
| Feb 13 | Oppenheimer | Upgrade | Perform → Outperform | — | $465.02 | $471.65 | +1.4% | +5.7% | +2.6% | +1.1% | +0.9% | +2.6% |
| Feb 13 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $465.02 | $471.65 | +1.4% | +5.7% | +2.6% | +1.1% | +0.9% | +2.6% |
| Feb 13 | Stifel | Maintains | Hold → Hold | — | $465.02 | $471.65 | +1.4% | +5.7% | +2.6% | +1.1% | +0.9% | +2.6% |
| Jan 28 | Barclays | Upgrade | Equal Weight → Overweight | — | $474.17 | $474.09 | -0.0% | +0.8% | +0.3% | -0.9% | -0.5% | -1.8% |
| Jan 26 | UBS | Maintains | Buy → Buy | — | $468.41 | $470.79 | +0.5% | +1.8% | +1.2% | +2.0% | +1.6% | +0.3% |
| Jan 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $467.35 | $465.23 | -0.5% | +0.2% | +2.0% | +1.5% | +2.3% | +1.8% |
| Jan 22 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $461.14 | $463.74 | +0.6% | +1.3% | +1.6% | +3.4% | +2.8% | +3.6% |
| Jan 12 | Bernstein | Upgrade | Market Perform → Outperform | — | $463.86 | $461.07 | -0.6% | -0.7% | -2.0% | -3.1% | -5.4% | -4.9% |
| Jan 6 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $448.80 | $454.85 | +1.3% | +4.4% | +7.9% | +4.7% | +3.4% | +2.6% |
| Dec 29 | Leerink Partners | Maintains | Outperform → Outperform | — | $462.90 | $463.00 | +0.0% | -0.7% | -2.0% | -2.1% | -2.3% | -3.0% |
| Dec 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $437.01 | $438.81 | +0.4% | +1.7% | +2.0% | +3.4% | +4.3% | +4.1% |
| Dec 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $457.36 | $457.78 | +0.1% | -0.4% | -3.3% | -4.4% | -2.8% | -2.5% |
| Dec 3 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $433.15 | $440.31 | +1.7% | +6.9% | +5.6% | +5.2% | +2.1% | +0.9% |
| Nov 7 | UBS | Maintains | Buy → Buy | — | $416.25 | $415.61 | -0.2% | -1.6% | +1.2% | +3.1% | +4.3% | +4.4% |
| Nov 4 | Barclays | Maintains | Equal Weight → Equal Weight | — | $426.00 | $418.55 | -1.7% | -1.0% | -2.1% | -2.3% | -3.9% | -1.1% |
| Nov 4 | Stifel | Maintains | Hold → Hold | — | $426.00 | $418.55 | -1.7% | -1.0% | -2.1% | -2.3% | -3.9% | -1.1% |
| Nov 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $426.00 | $418.55 | -1.7% | -1.0% | -2.1% | -2.3% | -3.9% | -1.1% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $414.86 | $413.33 | -0.4% | -1.7% | -1.8% | -0.6% | -1.7% | -1.5% |
| Oct 8 | JP Morgan | Maintains | Overweight → Overweight | — | $410.28 | $410.93 | +0.2% | +2.6% | +1.1% | -0.6% | -0.7% | +0.5% |
| Oct 2 | Citigroup | Maintains | Buy → Buy | — | $404.21 | $404.21 | +0.0% | +1.1% | -0.2% | -0.3% | +1.5% | +4.2% |
| Sep 25 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $376.62 | $383.20 | +1.7% | +1.4% | +2.4% | +5.0% | +4.0% | +7.3% |
| Sep 11 | Evercore ISI | Maintains | Outperform → Outperform | — | $388.55 | $388.55 | +0.0% | +2.3% | +1.5% | +1.2% | +0.7% | -0.4% |
| Aug 7 | Citigroup | Maintains | Buy → Buy | — | $385.65 | $385.00 | -0.2% | -2.6% | -5.0% | -2.9% | +0.5% | +2.7% |
| Aug 6 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $374.98 | $375.76 | +0.2% | +2.8% | +0.2% | -2.3% | -0.1% | +3.4% |
| Aug 6 | Guggenheim | Maintains | Buy → Buy | — | $374.98 | $375.76 | +0.2% | +2.8% | +0.2% | -2.3% | -0.1% | +3.4% |
| Aug 6 | Canaccord Genuity | Maintains | Hold → Hold | — | $374.98 | $375.76 | +0.2% | +2.8% | +0.2% | -2.3% | -0.1% | +3.4% |
| Aug 5 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $472.27 | $408.22 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% |
| Aug 5 | Truist | Maintains | Buy → Buy | — | $472.27 | $408.22 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% |
| Aug 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $472.27 | $408.22 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% |
| Aug 5 | BMO Capital | Maintains | Outperform → Outperform | — | $472.27 | $408.22 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $472.27 | $408.22 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% |
| Aug 5 | UBS | Maintains | Buy → Buy | — | $472.27 | $408.22 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% |
| Aug 5 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $472.27 | $408.22 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% |
| Aug 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $472.27 | $408.22 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% |
| Aug 5 | Stifel | Maintains | Hold → Hold | — | $472.27 | $408.22 | -13.6% | -20.6% | -18.3% | -20.5% | -22.4% | -20.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Bhatia Sangeeta N.Dir | — | Sell | 318 | $423.73 | $135K | 4,924 | +0.78% | — |
| May 1, 2026 | Liu JoyOff | EVP and Chief Legal Officer | Sell | 1,104 | $425.02 | $469K | 20,729 | +0.78% | — |
8-K · 5.02
!!! Very High
Vertex Pharmaceuticals Inc -- 8-K 5.02: Executive Change
Vertex Pharmaceuticals appointed and simultaneously had Suketu Upadhyay resign as director, suggesting a potential leadership transition or restructuring that investors should monitor for strategic implications.
Apr 29
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
VRTX's vague forward-looking statement caution suggests upcoming announcements may disappoint if projections don't materialize, warranting investor caution on stock volatility.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Absci's rapid progression of AI-designed ABS-201 into human trials with positive safety signals validates its platform technology, potentially justifying higher valuations if clinical efficacy data continues to impress investors.
Mar 24
8-K
Vertex Pharmaceuticals Inc -- 8-K Filing
Vertex Pharmaceuticals expects accelerated FDA approval of povetacicept for IgAN in the first half of 2026, potentially adding a new revenue stream while the company advances its cystic fibrosis and gene therapy portfolios.
Feb 12
Data updated apr 27, 2026 8:11am
· Source: massive.com